Maze shares jump after Vertex kidney drug study results
Maze Therapeutics shares rose after Vertex reported positive study results for its kidney disease drug, implying strong commercial potential for genetic kidney disease treatments.
Shares of biopharmaceutical company Maze Therapeutics jumped after competitor Vertex Pharmaceuticals reported positive study results for its kidney disease drug, signaling strong commercial potential for treatments targeting genetic kidney disease. Vertex researchers…